SL-BUP

Phase 2Small molecule

NNYU Langone Health

SL-BUP is one of 3 small molecule programs targeting Opioid Use Disorder (OUD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid Use Disorder (OUD)Active, not recruiting

Opioid Use Disorder (OUD)Phase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Opioid Use Disorder (OUD)

#DrugCompanyPhaseTrials

XR-NTX

NNYU Langone Health

Phase 2

1 2

SL-BUP

NNYU Langone Health

Phase 2

1 3

Methadone Hydrochloride

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Opioid Use Disorder (OUD)

NCT04464980

Clinical

Trials by Indication[1]

Opioid Use Disorder (OUD)1 trial

NIDA-CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Active, not recruiting·NNYU Langone Health·Phase 2·NCT04464980·1,516 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SL-BUP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SL-BUP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SL-BUP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNYU Langone Health

SL-BUP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Opioid Use Disorder (OUD)1 trial

References

Drug Info

Quick Facts

Related News